About UNTHSC Scholar

Contact scholar@unthsc.edu for more information on how to submit your work.

UNTHSC Scholar is an open access repository of the intellectual output and publicly available materials of the university. UNTHSC Scholar provides stable access to data, highlights community partnerships and engagement, and enables discovery of these works by the international scientific community. It preserves the history, growth and innovation of the University of North Texas Health Science Center as an institution.

Communities in UNTHSC Scholar

Select a community to browse its collections.

Now showing 1 - 16 of 16

Recent Submissions

Item

LAV Report : Library News & Promotions

(University of North Texas Health Science Center, 2024-07-01) Gibson D. Lewis Health Science Library

Item

LAV Report : Library News & Promotions

(University of North Texas Health Science Center, 2024-06-01) Gibson D. Lewis Health Science Library

Item

LAV Report : Library News & Promotions

(University of North Texas Health Science Center, 2024-05-01) Gibson D. Lewis Health Science Library

Item

Carvedilol, an alternative for lowering liver stiffness in patients with cirrhosis and portal hypertension

(2024-05) Guriginjakunta, Niharika; Sankpal, Umesh; Heck, Amber J.

Liver cirrhosis, often associated with portal hypertension, presents a significant health burden globally. Carvedilol, a non-selective beta-blocker, has emerged as a promising therapeutic option for managing portal hypertension in patients with liver cirrhosis. This retrospective analysis assessed the effect of Carvedilol treatment on patients with liver cirrhosis and clinically suspected portal hypertension, focusing on its effects on liver function parameters, non-invasive fibrosis scores, and liver stiffness measurements. A total of 130 patients from the Liver Center of Texas were included in this retrospective analysis, comprising 65 patients in the treatment group receiving Carvedilol and 65 patients in the control group. Statistical analyses, including t-tests, were conducted to assess the differences between groups. Carvedilol treatment led to significant improvements in liver function parameters, including a reduction in AST levels, indicative of improved liver function. Non-invasive fibrosis scores, such as FIB-4, AGILE 3, AGILE 4, and APRI, showed notable improvements after Carvedilol treatment in the treatment group, suggesting a reduction in liver fibrosis and improved prognosis. Liver stiffness measurements using eKpa and CAP scores demonstrated significant reductions after Carvedilol treatment within the treatment group, indicating improved liver stiffness. The study suggests that Carvedilol is effective in managing portal hypertension in patients with liver cirrhosis. Further research is needed to confirm these findings in larger cohorts and evaluate the long-term efficacy, and safety of Carvedilol treatment. Additionally, addressing disparities in liver disease diagnosis and treatment is crucial for improving outcomes and reducing the burden of liver-related morbidity and mortality.

Item

Comparative Patient Outcome Analysis Between Two Radiation Therapies for Head and Neck Cancers

(2023-05) Stein, Maggie J.; Ranjan, Amalendu P.; Basha, Riyaz; Neufeld, Sarah; Desai, Kajal